What is the dosage for Femara (letrozole) in breast cancer treatment?

The correct dosage for Femara (letrozole) in breast cancer treatment is 2.5 mg daily. Femara is an aromatase inhibitor commonly used for the postoperative treatment of hormone receptor-positive breast cancer in postmenopausal women. The standard dosing of 2.5 mg daily is based on clinical studies that have demonstrated its effectiveness in reducing the risk of cancer recurrence.

Studies have shown that this dosage is both well-tolerated and effective in lowering estrogen levels significantly, which is crucial for patients whose breast cancer is driven by estrogen. The dosing schedule is designed to maintain consistent drug levels in the body, optimizing therapeutic effects while minimizing potential side effects.

Other dosage options, while they may appear plausible, do not align with current clinical guidelines or the evidence supporting letrozole's use in breast cancer. Lower dosages do not provide adequate therapeutic benefit, and higher dosages could lead to increased side effects without improving outcomes. Thus, the established and effective dose remains at 2.5 mg daily.